Q4 2026 Kestra Medical Technologies Ltd Earnings Call Transcript
Key Points
- Kestra Medical Technologies Ltd (KMTS) reported a 66% increase in revenue for the fourth quarter, reaching $28.6 million, driven by a 63% year-over-year increase in prescriptions.
- The company achieved a gross margin of 54.8%, marking the tenth consecutive quarter of sequential gross margin expansion.
- KMTS expanded its sales territories from 80 to 130, enhancing its market penetration and sales force productivity.
- The ASSURE system's clinical evidence and innovation, including a new detection algorithm, have strengthened its competitive position in the wearable cardioverter defibrillator (WCD) market.
- KMTS secured a $200 million term loan facility, providing financial flexibility to invest in growth opportunities and potential acquisitions.
- Despite strong revenue growth, KMTS reported a GAAP net loss of $38.8 million for the fourth quarter.
- Operating expenses increased to $55 million, primarily due to investments in the commercial organization and revenue cycle management capabilities.
- The company's adjusted EBITDA loss widened to $26.7 million in the fourth quarter compared to the prior-year period.
- KMTS's operating cash burn, although reduced, remains significant at $18.7 million for the fourth quarter.
- The company faces challenges in fully penetrating existing territories, with some sales reps managing an unmanageable number of accounts.
Good afternoon, and welcome to Kestra Medical Technologies fourth-quarter fiscal 2026 earnings conference call. This conference call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Neil Bhalodkar, Vice President of Investor Relations, for introductory comments.
Thank you, Carmen. Good afternoon. Thank you for joining Kestra's fourth-quarter fiscal 2026 earnings call. With me today are Brian Webster, President and Chief Executive Officer; and Vaseem Mahboob, Chief Financial Officer.
This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements are made on this call that do not relate to matters of historical fact should be considered forward-looking statements. These statements are based on Kestra's current expectations, forecasts and assumptions, which are subject to inherent uncertainties, risks and assumptions that are difficult
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
